№ lp_1_02928
File format: docx
Character count: 61241
File size: 463 KB
These guidelines outline the expected practices for pharmacists involved in compounding medicines for human and animal patients.
Year:
2023
Region / city:
Australia
Subject:
Pharmaceutical compounding guidelines
Document Type:
Guideline
Organization / Institution:
Pharmacy Board of Australia
Author:
Pharmacy Board of Australia
Target Audience:
Registered pharmacists, education providers, employers
Period of validity:
Indefinite
Approval Date:
Not specified
Date of amendments:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2016
Region / City:
Australia
Topic:
Pharmacy, Medicine Compounding
Document Type:
Consultation Response
Organization:
Pharmaceutical Society of Australia
Author:
Dr Lance Emerson, Chief Executive Officer
Target Audience:
Pharmacists, Pharmacy Regulators
Period of Validity:
Indefinite
Approval Date:
1 February 2016
Date of Amendments:
None
Contextual Description:
Document is a public consultation response discussing terminology issues and proposed updates regarding compounded parenteral medicines, primarily aimed at Australian pharmacists.
Year:
2025
Region / City:
Washington
Topic:
Pharmacy, Pharmaceutical Regulations
Document Type:
Self-Inspection Worksheet
Organization / Institution:
WA Pharmacy Quality Assurance Commission
Author:
Not specified
Target Audience:
Pharmacy Managers, Pharmacists
Effective Period:
March 2025
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / city:
California
Topic:
Veterinary compounding, legal requirements, inspection, best practices
Document Type:
Regulatory guidelines
Organization:
Veterinary Medical Board (VMB)
Author:
California State Government
Target Audience:
Veterinarians, veterinary facilities
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Organisation name:
Australian Custom Pharmaceuticals Pty Ltd
Contact name:
Daryll Knowles
E-mail address:
[content redacted]
Date:
1 February 2016
Region:
Australia
Topic:
Pharmacy Guidelines
Document type:
Consultation Paper
Institution:
Pharmacy Board of Australia
Target audience:
Pharmacists, Compounding Professionals
Period of validity:
Indefinite
Approval date:
Not specified
Amendment date:
Not specified
Year:
2006
Region / City:
India
Subject:
Electricity theft and compounding procedure
Document Type:
Commercial Circular
Issuing Authority:
Chief Engineer (Commercial)
References:
Commercial Circular Nos. 17 (18.10.2005), 31 (09.02.2006), 32 (28.03.2006)
Legal Basis:
Section 152, Electricity Act 2003
Target Audience:
Electricity supply officers and authorized personnel
Procedure Included:
Guidelines for reconnection and compounding charges
Action Required:
Payment verification and record entry in consumer ledger
Distribution:
As per mailing list
Year:
2026
Region / City:
Manchester, United Kingdom
Subject:
Graphene, Compounding, Nanomaterials
Document Type:
Press Release
Organization:
HydroGraph Clean Power Inc.
Author:
Matt Kreps, Vice President of Investor Relations
Target Audience:
Industry professionals, investors
Effective Period:
February 10, 2026
Approval Date:
February 10, 2026
Date of Changes:
None
Note:
Description
Year:
2016
Region / City:
Suffolk County, Massachusetts
Theme:
Pharmacy Regulations
Document Type:
Agreement
Organization / Institution:
Massachusetts Board of Registration in Pharmacy
Author:
Massachusetts Board of Registration in Pharmacy
Target Audience:
Licensed Pharmacists, Pharmacy Organizations, Regulatory Authorities
Period of Effect:
1 year (from the Effective Date)
Approval Date:
6/26/2019
Date of Changes:
7/8/2019
Year:
2026
Region / City:
United States
Subject:
Pharmacy compounding and regulatory compliance
Document Type:
Inspection checklist / Compliance report
Regulatory Authority:
FDA, DEA, State Pharmacy Boards
Pharmacy Name:
Not specified
Store Number:
Not specified
Address:
Not specified
Manager of Record:
Not specified
Inspection Dates:
Not specified
Compounding Risk Level:
Simple / Moderate / Complex
Compounded Products:
Non-sterile medications, dietary/nutritional supplements
Target Audience:
Pharmacy staff, regulatory inspectors
Operating Hours:
M–F, Sat, Sun
Licenses:
Pharmacy license, MOR license
Storage Monitoring:
Temperature and conditions monitoring for drugs and components
Year:
2023
Country:
Mozambique
Region:
Africa Region
Theme:
Poverty, inequality, labor market, and economic vulnerability
Document Type:
Poverty assessment report
Institution:
World Bank
Department:
Poverty and Equity Global Practice
Subject Areas:
Economic growth, inequality, labor markets, fiscal policy, climate shocks, and social welfare
Geographic Scope:
National analysis with provincial comparisons
Time Period Covered:
Approximately 1996–2023 with detailed analysis for 2014/15–2019/20 and 2015–2020
Key Topics:
COVID-19 impacts on poverty, multidimensional deprivation, inequality trends, labor market conditions, fiscal incidence, climate and weather shocks
Data Sources:
Household surveys, national accounts, fiscal incidence analysis, and poverty measurement frameworks
Analytical Components:
Statistical analysis, poverty trends, inequality measurement, labor market profiling, and policy considerations
Annexes:
Poverty measurement, inequality analysis, labor market decomposition, fiscal incidence analysis, and climate shock modelling
Year:
2024
Type of document:
Policies and procedures manual
Subject:
Non-sterile pharmacy compounding
Organization:
Alberta College of Pharmacy (ACP)
Responsible individuals:
Compounding Supervisor and other staff involved
Last updated:
Month/Day/Year
Last reviewed:
Month/Day/Year
References updated:
February 5, 2024
Target audience:
Pharmacy personnel
Sections included:
General operations, personnel and facilities, compounded preparations, quality assurance, additional resources
Year:
2023
Location:
Udon Thani, Thailand
Topic:
Healthcare Economics
Document Type:
Cost Analysis Report
Institution:
Udon Thani Cancer Hospital
Author:
Not specified
Target Audience:
Hospital Administrators, Health Economists
Data Collection Period:
October 2022 – September 2023
Costing Method:
Standard (conventional) costing
Cost Centers:
Absorbing and Transient
Cost Components:
Labor, Material, Capital, Indirect Costs
Exclusions:
Chemotherapy drug costs
Year:
2016
Region / City:
Australia
Topic:
Pharmacy, Medicine Compounding
Document Type:
Consultation Response
Organization:
Pharmaceutical Society of Australia
Author:
Dr Lance Emerson, Chief Executive Officer
Target Audience:
Pharmacists, Pharmacy Regulators
Period of Validity:
Indefinite
Approval Date:
1 February 2016
Date of Amendments:
None
Contextual Description:
Document is a public consultation response discussing terminology issues and proposed updates regarding compounded parenteral medicines, primarily aimed at Australian pharmacists.
Organisation:
Canberra Health Services
Document type:
Guideline
Reference number:
CHS25/225
Jurisdiction:
Australian Capital Territory
Healthcare setting:
Public health services
Subject area:
Medication management
Professional scope:
Nursing and midwifery practice
Approved by:
Drug and Therapeutics Committee
Target professionals:
Registered nurses and registered midwives
Patient groups:
Adults, children 12 years or older, and selected medicines for children under 12 years
Exclusions:
Neonates, Special Care Nursery patients, Neonatal Intensive Care Unit patients
Regulatory framework:
Australian medicines scheduling (Schedules 2, 3, 4, and 8)
Content components:
Governance, safe use, documentation, approved medicine lists
Year:
2023
Region / city:
European Union
Topic:
Pharmaceutical technology development
Document type:
Briefing document
Organization:
European Medicines Agency
Author:
Not specified
Target audience:
Pharmaceutical experts, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
Not specified
This document is a briefing source for discussing pharmaceutical technology and regulatory aspects at a QIG 1:
1 meeting.
Year:
2023
Country:
Australia
Topic:
Opioid dependence treatment
Document type:
Information overview
Program:
ODT Community Pharmacy Program
Administering body:
Pharmacy Programs Administrator
Related scheme:
Pharmaceutical Benefits Scheme
Legislative framework:
National Health (Highly specialised drugs program) Special Arrangement 2021
Target audience:
Community pharmacists and hospital pharmacists
Effective date:
1 July 2023
Funding period:
2023–24 to 2026–27
Medicines covered:
Methadone, buprenorphine, buprenorphine with naloxone
Regulatory classification:
Schedule 8 controlled drugs
Source type:
Government health program guidance
Document type:
Q&A guidance
Jurisdiction:
Japan
Subject:
Import and shipment of medicines and medical devices
Issuing authority:
Ministry of Health, Labour and Welfare
Intended users:
Individuals importing or sending medicines for personal use
Scope:
Prescription medicines, injections, syringes, and medical devices
Import purpose:
Personal use
Regulatory framework:
Pharmaceutical and Medical Device regulations
Application system:
Online Import Confirmation system
Related forms:
Import Confirmation Application Form (Form 12); Explanation of Pharmaceutical Product (Form 13)
Year:
2024
Region / city:
Denmark
Topic:
Medicine, Health Economics
Document type:
Template
Organization / institution:
Danish Medicines Council
Author:
Danish Medicines Council
Target audience:
Pharmaceutical companies
Period of validity:
Ongoing
Approval date:
10 September 2024
Date of changes:
1 April 2025
Version:
2.5
Year:
2021
Region / city:
Victoria, Australia
Theme:
Pharmacist regulations
Document type:
Legislative guideline
Agency / institution:
Medicines and Poisons Regulation (MPR)
Author:
Medicines and Poisons Regulation (MPR)
Target audience:
Health practitioners, pharmacists
Period of validity:
Ongoing
Approval date:
2017
Date of amendments:
2021
Context:
This document provides guidelines for pharmacists regarding the dispensing, administration, and supply of Schedule 4 and 8 medicines in Victoria, Australia, as outlined in the Drugs Poisons and Controlled Substances Act 1981 and related regulations.
Year:
2020
Region / city:
UK
Theme:
Medicines Information
Document type:
List
Organization / institution:
NHS
Author:
UKMi
Target audience:
NHS Medicines Information Services
Period of validity:
Ongoing, updated quarterly
Approval date:
November 2020
Date of changes:
May 2020